Current pharmacological treatments for COVID‐19: What's next?
Since December 2019 SARS‐Cov‐2 was found responsible for the disease COVID‐19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID‐19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir...
Gespeichert in:
| Veröffentlicht in: | British journal of pharmacology 2020-11, Vol.177 (21), p.4813-4824 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 4824 |
|---|---|
| container_issue | 21 |
| container_start_page | 4813 |
| container_title | British journal of pharmacology |
| container_volume | 177 |
| creator | Scavone, Cristina Brusco, Simona Bertini, Michele Sportiello, Liberata Rafaniello, Concetta Zoccoli, Alice Berrino, Liberato Racagni, Giorgio Rossi, Francesco Capuano, Annalisa |
| description | Since December 2019 SARS‐Cov‐2 was found responsible for the disease COVID‐19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID‐19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID‐19, focusing on their antiviral, immune‐modulatory and/or anti‐inflammatory actions. Where available, data from clinical trials involving patients with COVID‐19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID‐19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID‐19 and reducing its symptoms and complications.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc |
| doi_str_mv | 10.1111/bph.15072 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7264618</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2451916409</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5772-5584471bb8c5a64990dc0c77c87cec0ead50dc60bbb23fd4a4eca89aa1c18aad3</originalsourceid><addsrcrecordid>eNp1kLtOwzAYhS0EoqUw8AIoEgNiSGsnduwwUEG4tFIlGLiM1h_HaVMlTXESoBuPwDPyJBhaKhjwYsnn0-ejg9A-wV1iTy-eT7qEYe5toDahPHCZL8gmamOMuUuIEC20U1VTjG3I2TZq-Z7vhczDbdSPGmP0rHbmEzAFqDIvx5mC3KmNhrqwSeWkpXGim4fhxcfbOwlPnMcJ1EeVM9OvdX8XbaWQV3pvdXfQ_dXlXTRwRzfXw-hs5CrGuecyJijlJI6FYhDQMMSJwopzJbjSCmtImH0JcBzHnp8mFKhWIEIAoogASPwOOl16501c6ETZYgZyOTdZAWYhS8jk32SWTeS4fJbcC2hAhBUcrgSmfGp0Vctp2ZiZ7Sw9ykhIAopDSx0vKWXKqjI6Xf9AsPzaWtqt5ffWlj34XWlN_oxrgd4SeMlyvfjfJM9vB0vlJ4KPibc</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2451916409</pqid></control><display><type>article</type><title>Current pharmacological treatments for COVID‐19: What's next?</title><source>Wiley Free Content</source><source>MEDLINE</source><source>Wiley Online Library Journals Frontfile Complete</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Scavone, Cristina ; Brusco, Simona ; Bertini, Michele ; Sportiello, Liberata ; Rafaniello, Concetta ; Zoccoli, Alice ; Berrino, Liberato ; Racagni, Giorgio ; Rossi, Francesco ; Capuano, Annalisa</creator><creatorcontrib>Scavone, Cristina ; Brusco, Simona ; Bertini, Michele ; Sportiello, Liberata ; Rafaniello, Concetta ; Zoccoli, Alice ; Berrino, Liberato ; Racagni, Giorgio ; Rossi, Francesco ; Capuano, Annalisa</creatorcontrib><description>Since December 2019 SARS‐Cov‐2 was found responsible for the disease COVID‐19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID‐19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID‐19, focusing on their antiviral, immune‐modulatory and/or anti‐inflammatory actions. Where available, data from clinical trials involving patients with COVID‐19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID‐19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID‐19 and reducing its symptoms and complications.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</description><identifier>ISSN: 0007-1188</identifier><identifier>EISSN: 1476-5381</identifier><identifier>DOI: 10.1111/bph.15072</identifier><identifier>PMID: 32329520</identifier><language>eng</language><publisher>England: Blackwell Publishing Ltd</publisher><subject>Animals ; antiinflammatory agents ; Antiviral agents ; Antiviral Agents - administration & dosage ; Antiviral Agents - adverse effects ; Antiviral Agents - pharmacology ; Antiviral drugs ; antivirals ; Betacoronavirus - isolation & purification ; clinical practice ; clinical research ; Clinical trials ; Coronavirus Infections - drug therapy ; Coronavirus Infections - virology ; COVID-19 ; Drug Repositioning ; Drug therapy ; Drugs ; Humans ; Immunosuppressive agents ; immuno‐modulatory agents ; Inflammation ; Lopinavir ; Pandemics ; Patients ; pharmacological treatments ; Pneumonia, Viral - drug therapy ; Pneumonia, Viral - virology ; Review ; Ritonavir ; SARS-CoV-2 ; Severe acute respiratory syndrome coronavirus 2 ; Themed Issue: Review ; Vaccines</subject><ispartof>British journal of pharmacology, 2020-11, Vol.177 (21), p.4813-4824</ispartof><rights>2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society</rights><rights>2020 The Authors. British Journal of Pharmacology published by John Wiley & Sons Ltd on behalf of British Pharmacological Society.</rights><rights>2020. This article is published under http://creativecommons.org/licenses/by-nc/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5772-5584471bb8c5a64990dc0c77c87cec0ead50dc60bbb23fd4a4eca89aa1c18aad3</citedby><cites>FETCH-LOGICAL-c5772-5584471bb8c5a64990dc0c77c87cec0ead50dc60bbb23fd4a4eca89aa1c18aad3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264618/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC7264618/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,881,1411,1427,27901,27902,45550,45551,46384,46808,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32329520$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Scavone, Cristina</creatorcontrib><creatorcontrib>Brusco, Simona</creatorcontrib><creatorcontrib>Bertini, Michele</creatorcontrib><creatorcontrib>Sportiello, Liberata</creatorcontrib><creatorcontrib>Rafaniello, Concetta</creatorcontrib><creatorcontrib>Zoccoli, Alice</creatorcontrib><creatorcontrib>Berrino, Liberato</creatorcontrib><creatorcontrib>Racagni, Giorgio</creatorcontrib><creatorcontrib>Rossi, Francesco</creatorcontrib><creatorcontrib>Capuano, Annalisa</creatorcontrib><title>Current pharmacological treatments for COVID‐19: What's next?</title><title>British journal of pharmacology</title><addtitle>Br J Pharmacol</addtitle><description>Since December 2019 SARS‐Cov‐2 was found responsible for the disease COVID‐19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID‐19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID‐19, focusing on their antiviral, immune‐modulatory and/or anti‐inflammatory actions. Where available, data from clinical trials involving patients with COVID‐19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID‐19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID‐19 and reducing its symptoms and complications.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</description><subject>Animals</subject><subject>antiinflammatory agents</subject><subject>Antiviral agents</subject><subject>Antiviral Agents - administration & dosage</subject><subject>Antiviral Agents - adverse effects</subject><subject>Antiviral Agents - pharmacology</subject><subject>Antiviral drugs</subject><subject>antivirals</subject><subject>Betacoronavirus - isolation & purification</subject><subject>clinical practice</subject><subject>clinical research</subject><subject>Clinical trials</subject><subject>Coronavirus Infections - drug therapy</subject><subject>Coronavirus Infections - virology</subject><subject>COVID-19</subject><subject>Drug Repositioning</subject><subject>Drug therapy</subject><subject>Drugs</subject><subject>Humans</subject><subject>Immunosuppressive agents</subject><subject>immuno‐modulatory agents</subject><subject>Inflammation</subject><subject>Lopinavir</subject><subject>Pandemics</subject><subject>Patients</subject><subject>pharmacological treatments</subject><subject>Pneumonia, Viral - drug therapy</subject><subject>Pneumonia, Viral - virology</subject><subject>Review</subject><subject>Ritonavir</subject><subject>SARS-CoV-2</subject><subject>Severe acute respiratory syndrome coronavirus 2</subject><subject>Themed Issue: Review</subject><subject>Vaccines</subject><issn>0007-1188</issn><issn>1476-5381</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>EIF</sourceid><recordid>eNp1kLtOwzAYhS0EoqUw8AIoEgNiSGsnduwwUEG4tFIlGLiM1h_HaVMlTXESoBuPwDPyJBhaKhjwYsnn0-ejg9A-wV1iTy-eT7qEYe5toDahPHCZL8gmamOMuUuIEC20U1VTjG3I2TZq-Z7vhczDbdSPGmP0rHbmEzAFqDIvx5mC3KmNhrqwSeWkpXGim4fhxcfbOwlPnMcJ1EeVM9OvdX8XbaWQV3pvdXfQ_dXlXTRwRzfXw-hs5CrGuecyJijlJI6FYhDQMMSJwopzJbjSCmtImH0JcBzHnp8mFKhWIEIAoogASPwOOl16501c6ETZYgZyOTdZAWYhS8jk32SWTeS4fJbcC2hAhBUcrgSmfGp0Vctp2ZiZ7Sw9ykhIAopDSx0vKWXKqjI6Xf9AsPzaWtqt5ffWlj34XWlN_oxrgd4SeMlyvfjfJM9vB0vlJ4KPibc</recordid><startdate>202011</startdate><enddate>202011</enddate><creator>Scavone, Cristina</creator><creator>Brusco, Simona</creator><creator>Bertini, Michele</creator><creator>Sportiello, Liberata</creator><creator>Rafaniello, Concetta</creator><creator>Zoccoli, Alice</creator><creator>Berrino, Liberato</creator><creator>Racagni, Giorgio</creator><creator>Rossi, Francesco</creator><creator>Capuano, Annalisa</creator><general>Blackwell Publishing Ltd</general><general>John Wiley and Sons Inc</general><scope>24P</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7TK</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>5PM</scope></search><sort><creationdate>202011</creationdate><title>Current pharmacological treatments for COVID‐19: What's next?</title><author>Scavone, Cristina ; Brusco, Simona ; Bertini, Michele ; Sportiello, Liberata ; Rafaniello, Concetta ; Zoccoli, Alice ; Berrino, Liberato ; Racagni, Giorgio ; Rossi, Francesco ; Capuano, Annalisa</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5772-5584471bb8c5a64990dc0c77c87cec0ead50dc60bbb23fd4a4eca89aa1c18aad3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Animals</topic><topic>antiinflammatory agents</topic><topic>Antiviral agents</topic><topic>Antiviral Agents - administration & dosage</topic><topic>Antiviral Agents - adverse effects</topic><topic>Antiviral Agents - pharmacology</topic><topic>Antiviral drugs</topic><topic>antivirals</topic><topic>Betacoronavirus - isolation & purification</topic><topic>clinical practice</topic><topic>clinical research</topic><topic>Clinical trials</topic><topic>Coronavirus Infections - drug therapy</topic><topic>Coronavirus Infections - virology</topic><topic>COVID-19</topic><topic>Drug Repositioning</topic><topic>Drug therapy</topic><topic>Drugs</topic><topic>Humans</topic><topic>Immunosuppressive agents</topic><topic>immuno‐modulatory agents</topic><topic>Inflammation</topic><topic>Lopinavir</topic><topic>Pandemics</topic><topic>Patients</topic><topic>pharmacological treatments</topic><topic>Pneumonia, Viral - drug therapy</topic><topic>Pneumonia, Viral - virology</topic><topic>Review</topic><topic>Ritonavir</topic><topic>SARS-CoV-2</topic><topic>Severe acute respiratory syndrome coronavirus 2</topic><topic>Themed Issue: Review</topic><topic>Vaccines</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Scavone, Cristina</creatorcontrib><creatorcontrib>Brusco, Simona</creatorcontrib><creatorcontrib>Bertini, Michele</creatorcontrib><creatorcontrib>Sportiello, Liberata</creatorcontrib><creatorcontrib>Rafaniello, Concetta</creatorcontrib><creatorcontrib>Zoccoli, Alice</creatorcontrib><creatorcontrib>Berrino, Liberato</creatorcontrib><creatorcontrib>Racagni, Giorgio</creatorcontrib><creatorcontrib>Rossi, Francesco</creatorcontrib><creatorcontrib>Capuano, Annalisa</creatorcontrib><collection>Wiley Online Library Open Access</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>Neurosciences Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>British journal of pharmacology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Scavone, Cristina</au><au>Brusco, Simona</au><au>Bertini, Michele</au><au>Sportiello, Liberata</au><au>Rafaniello, Concetta</au><au>Zoccoli, Alice</au><au>Berrino, Liberato</au><au>Racagni, Giorgio</au><au>Rossi, Francesco</au><au>Capuano, Annalisa</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Current pharmacological treatments for COVID‐19: What's next?</atitle><jtitle>British journal of pharmacology</jtitle><addtitle>Br J Pharmacol</addtitle><date>2020-11</date><risdate>2020</risdate><volume>177</volume><issue>21</issue><spage>4813</spage><epage>4824</epage><pages>4813-4824</pages><issn>0007-1188</issn><eissn>1476-5381</eissn><abstract>Since December 2019 SARS‐Cov‐2 was found responsible for the disease COVID‐19, which has spread worldwide. No specific therapies/vaccines are yet available for the treatment of COVID‐19. Drug repositioning may offer a strategy and a number of drugs have been repurposed, including lopinavir/ritonavir, remdesivir, favipiravir and tocilizumab. This paper describes the main pharmacological properties of such drugs administered to patients with COVID‐19, focusing on their antiviral, immune‐modulatory and/or anti‐inflammatory actions. Where available, data from clinical trials involving patients with COVID‐19 are reported. Preliminary clinical trials seem to support their benefit. However, such drugs in COVID‐19 patients have peculiar safety profiles. Thus, adequate clinical trials are necessary for these compounds. Nevertheless, while waiting for effective preventive measures i.e. vaccines, many clinical trials on drugs belonging to different therapeutic classes are currently underway. Their results will help us in defining the best way to treat COVID‐19 and reducing its symptoms and complications.
Linked Articles
This article is part of a themed issue on The Pharmacology of COVID‐19. To view the other articles in this section visit http://onlinelibrary.wiley.com/doi/10.1111/bph.v177.21/issuetoc</abstract><cop>England</cop><pub>Blackwell Publishing Ltd</pub><pmid>32329520</pmid><doi>10.1111/bph.15072</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0007-1188 |
| ispartof | British journal of pharmacology, 2020-11, Vol.177 (21), p.4813-4824 |
| issn | 0007-1188 1476-5381 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_7264618 |
| source | Wiley Free Content; MEDLINE; Wiley Online Library Journals Frontfile Complete; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Alma/SFX Local Collection |
| subjects | Animals antiinflammatory agents Antiviral agents Antiviral Agents - administration & dosage Antiviral Agents - adverse effects Antiviral Agents - pharmacology Antiviral drugs antivirals Betacoronavirus - isolation & purification clinical practice clinical research Clinical trials Coronavirus Infections - drug therapy Coronavirus Infections - virology COVID-19 Drug Repositioning Drug therapy Drugs Humans Immunosuppressive agents immuno‐modulatory agents Inflammation Lopinavir Pandemics Patients pharmacological treatments Pneumonia, Viral - drug therapy Pneumonia, Viral - virology Review Ritonavir SARS-CoV-2 Severe acute respiratory syndrome coronavirus 2 Themed Issue: Review Vaccines |
| title | Current pharmacological treatments for COVID‐19: What's next? |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-18T21%3A59%3A03IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Current%20pharmacological%20treatments%20for%20COVID%E2%80%9019:%20What's%20next?&rft.jtitle=British%20journal%20of%20pharmacology&rft.au=Scavone,%20Cristina&rft.date=2020-11&rft.volume=177&rft.issue=21&rft.spage=4813&rft.epage=4824&rft.pages=4813-4824&rft.issn=0007-1188&rft.eissn=1476-5381&rft_id=info:doi/10.1111/bph.15072&rft_dat=%3Cproquest_pubme%3E2451916409%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2451916409&rft_id=info:pmid/32329520&rfr_iscdi=true |